Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
University of North Carolina Health Care · University of North Carolina at Chapel Hill · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,487
total citations
- FWCI
- 99.44
- Percentile
- 100%
- References
- 31
Citations per year
Authors
8- JBJohn B. BuseCorresponding
University of North Carolina Health Care, University of North Carolina at Chapel Hill
- JRJulio Rosenstock
Dallas Diabetes Research Center
- GSGiorgio Sesti
Magna Graecia University
- WEWolfgang E. Schmidt
St. Josef-Hospital
- EMEduard Montanya
Institut d'Investigació Biomédica de Bellvitge, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Universitat de Barcelona
Topics & keywords
Topics
Keywords
- Exenatide
- Liraglutide
- Medicine
- Type 2 diabetes
- Metformin
- Internal medicine
- Endocrinology
- Population
No related works found for this paper.